Phoenix, Arizona, United States, November 18, 2026
AmBARI Healthcare, Inc., the Phoenix VA Health Care System, the Arizona Veterans Research and Education Foundation (AVREF) and the Young Blood Institute (YBI) have announced a Cooperative Research and Development Agreement (CRADA) to conduct a pilot clinical study evaluating an optimised Therapeutic Plasma Exchange (TPE) protocol in veterans with mild cognitive impairment (MCI) and prodromal Alzheimer’s disease. The collaborative research programme, known as the AmβARI study (VA Protocol #1859907), will investigate whether an extended full-volume plasma exchange procedure can influence the accumulation of amyloid proteins in the brain. The randomised, controlled study is expected to enrol up to 56 veterans and will be led by Principal Investigator S. Mitchell Harman, MD, PhD, at the Phoenix VA Health Care System. AmBARI Healthcare is funding the study through its partnership with the Young Blood Institute, with additional strategic partners contributing apheresis equipment, biomarker technologies and imaging capabilities. The agreement represents an important development in research exploring plasma-based approaches for Alzheimer’s disease and aims to generate clinical evidence in a controlled veteran population.
Pilot Study Evaluates Therapeutic Plasma Exchange
The AmβARI study will investigate an extended full-volume TPE protocol in veterans experiencing mild cognitive impairment or prodromal Alzheimer’s disease. Therapeutic Plasma Exchange is a medical procedure in which a patient’s plasma is separated from blood cells and removed, with replacement fluid introduced before the blood components are returned to the circulation. The procedure is already used in established medical settings for certain conditions, but its potential application in Alzheimer’s disease remains under investigation. Researchers are exploring whether removing circulating plasma components associated with amyloid accumulation could influence the balance of amyloid proteins between the bloodstream and the brain. The study will use a randomised, controlled design to assess the investigational protocol and compare outcomes between treatment groups. The planned enrolment of up to 56 participants will allow investigators to examine the feasibility and potential biological effects of the optimised procedure. The collaboration brings together the Phoenix VA’s clinical research infrastructure, the Arizona Veterans Research and Education Foundation’s research support and the Young Blood Institute’s experience in plasma-based therapeutic research. The protocol was developed by Dr. Harman in collaboration with YBI and AmBARI Global Principal Investigator Professor Colin Masters, MD, and other members of the investigative team.
PET-CT Imaging to Measure Brain Amyloid Levels
A key component of the clinical investigation is the use of advanced brain imaging to evaluate changes in amyloid burden. The study’s primary endpoint will use PET-CT imaging with the NAV-4694 tracer to quantify amyloid accumulation in the brain. NAV-4694 is an imaging tracer designed to detect amyloid deposits, allowing researchers to assess changes in brain amyloid levels over the course of the study. This approach is intended to provide an objective biological measure of the potential effects of the extended TPE protocol. The research is based partly on the hypothesis that human serum albumin can bind amyloid-beta proteins, including Aβ40 and Aβ42, in circulating blood. By removing plasma containing these and other circulating components, investigators aim to explore whether TPE could influence amyloid clearance from the brain. The study will also draw on biomarker and imaging technologies supplied by its strategic partners. Importantly, changes in PET imaging measurements would provide evidence about amyloid burden, but would not by themselves establish improvements in memory, cognition or everyday functioning. Further clinical assessments will be necessary to understand the potential significance of any observed imaging changes.
Previous Research Supports Further Alzheimer’s Investigation
The collaboration builds on earlier research involving plasma exchange in Alzheimer’s disease, including the AMBAR clinical trial, which investigated plasma exchange with albumin replacement in patients with mild-to-moderate Alzheimer’s disease. The announcement also references real-world experience at Ace Alzheimer Center Barcelona, where full-volume TPE procedures have been performed as part of its clinical programme. According to the organisations, findings from the AMBAR programme and experience at Ace Barcelona informed the development and optimisation of the current protocol. The Young Blood Institute has also reported preclinical research examining the relationship between plasma exchange and amyloid-beta clearance. These previous research efforts provide a scientific rationale for further investigation, but they do not establish that the optimised protocol will prevent or reverse Alzheimer’s disease. The new AmβARI study is specifically designed to evaluate the approach in a controlled group of veterans with mild cognitive impairment and prodromal Alzheimer’s disease. The research will operate under the oversight of the Phoenix VA Institutional Review Board (IRB) and applicable federal regulations. If successful, the study could provide additional evidence to guide larger clinical investigations. However, therapeutic plasma exchange for Alzheimer’s disease remains investigational, and further research will be required to establish its safety, effectiveness and potential role in clinical care.
Source: AmBARI Healthcare press release



